全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

重症肌无力伴胸腺瘤并发分泌性中耳炎1例并文献复习
A Case of Myasthenia Gravis with Thymoma Complicated by Secretory Otitis Media and Literature Review

DOI: 10.12677/acm.2024.1441333, PP. 2590-2594

Keywords: 重症肌无力,胸腺瘤,分泌性中耳炎,病例报告
Myasthenia Gravis
, Thymoma, Secretory Otitis Media, Case Report

Full-Text   Cite this paper   Add to My Lib

Abstract:

重症肌无力伴胸腺瘤是一种常见的获得性自身免疫性疾病,依据临床诊疗指南、影像学、组织学及实验室检查即可进行诊断及治疗,而伴发分泌性中耳炎的病例却鲜有报道。现报道1例25岁女性重症肌无力伴胸腺瘤并发分泌性中耳炎患者的临床资料,结合文献分析可能的致病机制及防治策略。
Myasthenia gravis with thymoma is a common acquired autoimmune disease, which can be diagnosed and treated based on clinical diagnosis and treatment guidelines, imaging, histology, and laboratory tests. However, there are few reports of cases accompanied by secretory otitis media. We report the clinical data of a 25-year-old female patient with myasthenia gravis accompanied by thymoma and secretory otitis media, and analyze the possible pathogenic mechanisms and prevention and treatment strategies based on literature review.

References

[1]  Sanders, D.B., Wolfe, G.I., Benatar, M., et al. (2016) International Consensus Guidance for Management of Myasthenia Gravis: Executive Summary. Neurology, 87, 419-425.
https://doi.org/10.1212/WNL.0000000000002790
[2]  Gilhus, N.E. and Verschuuren, J.J. (2015) Myasthenia Gravis: Subgroup Classification and Therapeutic Strategies. The Lancet Neurology, 14, 1023-1036.
https://doi.org/10.1016/S1474-4422(15)00145-3
[3]  García Estévez, D.A. and Pardo Fernández, J. (2023) Myasthenia Gravis. Update on Diagnosis and Therapy. Medicina Clinica, 161, 119-127.
https://doi.org/10.1016/j.medcle.2023.04.012
[4]  Berrih-Aknin, S., Frenkian-Cuvelier, M. and Eymard, B. (2014) Diagnostic and Clinical Classification of Autoimmune Myasthenia Gravis. Journal of Autoimmunity, 48-49, 143-148.
https://doi.org/10.1016/j.jaut.2014.01.003
[5]  Conti-Fine, B.M., Milani, M. and Kaminski, H.J. (2006) Myasthenia Gravis: Past, Present, and Future. The Journal of Clinical Investigation, 116, 2843-2854.
https://doi.org/10.1172/JCI29894
[6]  Su, M., Luo, Q., Wu, Z., et al. (2024) Thymoma-Associated Autoimmune Encephalitis with Myasthenia Gravis: Case Series and Literature Review. CNS Neuroscience & Therapeutics, 30, e14568.
https://doi.org/10.1111/cns.14568
[7]  刘玉红, 苏法仁. 分泌性中耳炎的相关发病机制及治疗研究[J]. 中华耳科学杂志, 2018, 16(2): 234-238.
[8]  Grob, D., Brunner, N., Namba, T., et al. (2008) Lifetime Course of Myasthenia Gravis. Muscle & Nerve, 37, 141-149.
https://doi.org/10.1002/mus.20950
[9]  Morren, J. and Li, Y. (2018) Myasthenia Gravis with Muscle-Specific Tyrosine Kinase Antibodies: A Narrative Review. Muscle & Nerve, 58, 344-358.
https://doi.org/10.1002/mus.26107
[10]  Nishino, M., Ashiku, S.K., Kocher, O.N., et al. (2017) The Thymus: A Comprehensive Review—Erratum. RadioGraphics, 37, 1004.
https://doi.org/10.1148/rg.2017174002
[11]  Morren, J.A. and Li, Y. (2023) Myasthenia Gravis: Frequently Asked Questions. Cleveland Clinic Journal of Medicine, 90, 103-113.
https://doi.org/10.3949/ccjm.90a.22017
[12]  Keesey, J. and Aarli, J. (2007) Something in the Blood? A History of the Autoimmune Hypothesis Regarding Myasthenia Gravis. Journal of the History of the Neurosciences, 16, 395-412.
https://doi.org/10.1080/09647040600675322
[13]  Maggi, L. and Mantegazza, R. (2011) Treatment of Myasthenia Gravis: Focus on Pyridostigmine. Clinical Drug Investigation, 31, 691-701.
https://doi.org/10.2165/11593300-000000000-00000
[14]  Salins, S., Teter, B., Kavak, K., et al. (2016) Low-Dose Medication and Long-Term Outcome in Myasthenia Gravis. Journal of Clinical Neuromuscular Disease, 18, 61-66.
https://doi.org/10.1097/CND.0000000000000122
[15]  Redaelli De Zinis, L.O., Parrinello, G., Schreiber, A., et al. (2013) Middle Ear Effusion in Patients with Sinonasal Cancer Treated by Surgery with or without Radiotherapy. Otolaryngology, 148, 619-624.
https://doi.org/10.1177/0194599812474798
[16]  Wang, S.Z., Wang, W.F., Zhang, H.Y., et al. (2007) Analysis of Anatomical Factors Controlling the Morbidity of Radiation-Induced Otitis Media with Effusion. Radiotherapy and Oncology, 85, 463-468.
https://doi.org/10.1016/j.radonc.2007.10.007
[17]  Sone, M., Kato, T., Arao, H., et al. (2013) Exploratory Findings of Audiometry in Adult Patients with Otitis Media with High Pepsinogen Concentrations: A Preliminary Study. Acta Oto-Laryngologica, 133, 35-41.
https://doi.org/10.3109/00016489.2012.715374
[18]  Tshifularo, M., Govender, L. and Monama, G. (2013) Otolaryngological, Head and Neck Manifestations in HIV-Infected Patients Seen at Steve Biko Academic Hospital in Pretoria, South Africa. South African Medical Journal, 103, 464-466.
https://doi.org/10.7196/SAMJ.6786
[19]  Kariya, S., Okano, M., Hattori, H., et al. (2006) TH1/TH2 and Regulatory Cytokines in Adults with Otitis Media with Effusion. Otology & Neurotology, 27, 1089-1093.
https://doi.org/10.1097/01.mao.0000224087.93096.4d
[20]  Zhao, S.Q., Li, J., Liu, H., et al. (2009) Role of Interleukin-10 and Transforming Growth Factor Beta 1 in Otitis Media with Effusion. Chinese Medical Journal, 122, 2149-2154.
[21]  Ondrey, F.G., Juhn, S.K. and Adams, G.L. (1998) Early-Response Cytokine Expression in Adult Middle Ear Effusions. OtolaryngologyHead and Neck Surgery, 119, 342-345.
https://doi.org/10.1016/S0194-5998(98)70075-0
[22]  Mills, R. and Hathorn, I. (2016) Aetiology and Pathology of Otitis Media with Effusion in Adult Life. The Journal of Laryngology and Otology, 130, 418-424.
https://doi.org/10.1017/S0022215116000943

Full-Text

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133